Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?

Basit Öğe Kaydı
dc.contributor.authorŞahin, Derya
dc.contributor.authorKızıl Çakar, Merih
dc.contributor.authorDal, Mehmet
dc.contributor.authorYiğenoğlu, Tuğçe Nur
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorUlu, Bahar
dc.date.accessioned2023-04-28T18:43:51Z
dc.date.available2023-04-28T18:43:51Z
dc.date.issued2021
dc.departmentRektörlük, Rektörlüğe Bağlı Birimler, NKÜ Dergileri
dc.description.abstractAim: Outcome for most patients with peripheral T-cell lymphomas (PTCLs) is poor, with low response rates and short durations of remission. We aimto analyze the outcome of PTCL patients who underwent autologous stem cell transplantation (ASCT) at our center and we researched whether firstcomplete remission (CR) was the optimal timing for ASCT in patients with PTCL.Materials and Methods: The data of PTCL patients who underwent ASCT between January 2010 and December 2020 at our center wereretrospectively analyzed.Results: Twenty-five patients with PTCL underwent ASCT. The median ASCT age was 44 years (range: 19-68). 68% of the patients were performedupfront ASCT after the first CR; 32% of the patients underwent ASCT after relapse or refractory (R/R) disease. The median follow-up time fromdiagnosis was 40 months (13-144 months). The five-year PFS and OS were 50.8% and 55.7%, respectively. Five-year OS was 82.4% in the up-frontASCT group, while the five-year OS was 15.6% in the R/R patients (p=0.019). The median OS was 25 months [95% confidence interval (CI): 0-50.4]in patients who had CR2, while it was 13 months (95% CI: 0-35) in patients who had PR before ASCT (p=0.03). According to subtypes of PTCL, OSand PFS were not statistically different in all groups (p=0.96 and p=0.79, respectively).Conclusion: Even the prognosis is poor in patients with PTCL, Overall survival was significantly longer among the upfront ASCT group. Patientsshould be consolidated with ASCT in the first CR, and relapse should not be waited to perform ASCT.
dc.identifier.doi10.4274/nkmj.galenos.2021.08108
dc.identifier.endpage212
dc.identifier.issn2587-0262
dc.identifier.issue2en_US
dc.identifier.startpage207
dc.identifier.trdizinid451037
dc.identifier.urihttps://doi.org10.4274/nkmj.galenos.2021.08108
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/451037
dc.identifier.urihttps://hdl.handle.net/20.500.11776/11739
dc.identifier.volume9
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.relation.ispartofNamık Kemal Tıp Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleIs the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11739.pdf
Boyut:
481.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Namık Kemal Tıp Dergisi